Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CytomX Therapeutics, Inc. - Common Stock (NQ:CTMX)

3.330 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about CytomX Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
Why CytomX Therapeutics Stock Was Skyrocketing This Week
One pundit believes the company might have a winning cancer drug in its pipeline. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million. 
Via Benzinga
What's going on in today's after hours session
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 12, 2025
 
Via Benzinga
Exploring CytomX Therapeutics's Earnings Expectations
 
Via Benzinga
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
CytomX (CTMX) Q2 Revenue Drops 26%
Via The Motley Fool
Topics Intellectual Property
CytomX Therapeutics Inc (NASDAQ:CTMX) Reports Q2 2025 Revenue Beat and Break-Even EPS
CytomX Therapeutics (CTMX) Q2 2025 revenue beat estimates at $18.66M, with break-even EPS. Shares rose slightly as clinical progress, including CX-2051 data, boosts optimism. 
Via Chartmill
This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
 
Via Benzinga
Deep Dive Into CytomX Therapeutics Stock: Analyst Perspectives (4 Ratings)
 
Via Benzinga
CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - A Strong Contender in High-Growth Biotech
CYTOMX THERAPEUTICS (CTMX) meets Minervini’s trend criteria with strong technicals and high-growth fundamentals, making it a candidate for momentum investors. 
Via Chartmill
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
This CytomX Therapeutics Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
 
Via Benzinga
CytomX Stock Hits 2-Month High After Upbeat Q1 Earnings, Promising Early Data For Cancer Drug
The company shared Phase 1 trial results for CX-2051, an antibody-drug conjugate for advanced colorectal cancer, with 28% of patients achieving confirmed partial responses. 
Via Stocktwits
Top movers analysis one hour before the close of the markets on 2025-05-12: top gainers and losers in today's session.
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Monday's session: most active stocks
These stocks are making the most noise in today's session. Stay tuned for the latest updates! 
Via Chartmill
Which stocks are moving on Monday?
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
These stocks are gapping in today's session
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report
CytomX reported early Phase 1 data for CX-2051 in advanced colorectal cancer, with a 94% disease control rate. 
Via Benzinga
Top movers in Monday's pre-market session
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Wondering what's happening in today's pre-market session?
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
These stocks are gapping in today's session
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.